Liver Cancer/HCC
Liver Cancer/HCC
AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- Details
- Category: Liver Cancer/HCC
- Published on Wednesday, 01 November 2017 00:00
- Written by Liz Highleyman
People with hepatitis B virus (HBV) who took an aspirin a day -- often recommended to help prevent cardiovascular disease -- had a lower risk of developing liver cancer, according to a study from Taiwan presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administration granted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 20 April 2017 00:00
- Written by Liz Highleyman
The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.
FDA Approves Nivolumab Immunotherapy for Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 12 October 2017 00:00
- Written by Liz Highleyman
In September, the U.S. Food and Drug Administrationgranted accelerated approval for nivolumab (Opdivo), an immunotherapy drug that restores T-cell anti-tumor activity, for people with hepatocellular carcinoma (HCC).
AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 15 December 2016 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), an antibody that blocks the PD-1 receptor and restores T-cell anti-tumor activity, appeared safe and was associated with disease control and stabilization in a Phase 1/2 study of patients with hepatocellular carcinoma, according to late-breaking results from the CheckMate 040 study presented at the AASLD Liver Meeting last month in Boston.
More Articles...
- Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer
- Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer
- ASCO 2015: PD-1 Checkpoint Inhibitor Nivolumab Shows Promise against Liver Cancer
Web Design and Development by